M&A Deal Summary

Ligand Pharmaceuticals Acquires Icagen - North Carolina Operations

On February 11, 2020, Ligand Pharmaceuticals acquired life science company Icagen - North Carolina Operations from Icagen for 15M USD

Acquisition Highlights
  • This is Ligand Pharmaceuticals’ 9th transaction in the Life Science sector.
  • This is Ligand Pharmaceuticals’ 10th largest (disclosed) transaction.
  • This is Ligand Pharmaceuticals’ 9th transaction in the United States.
  • This is Ligand Pharmaceuticals’ 1st transaction in North Carolina.

M&A Deal Summary
Date 2020-02-11
Target Icagen - North Carolina Operations
Sector Life Science
Buyer(s) Ligand Pharmaceuticals
Sellers(s) Icagen
Deal Type Divestiture
Deal Value 15M USD

Target

Icagen - North Carolina Operations

North Carolina, United States
Icagen, Inc. - North Carolina Operations includes partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ligand Pharmaceuticals

Jupiter, California, United States
Category Company
Founded 1987
Sector Life Science
Employees58
Revenue 131M USD (2023)
DESCRIPTION

Ligand Pharmaceuticals is a pharmaceutical company, develops products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand Pharmaceuticals was founded in 1987 and is based in Jupiter, Florida.

DEAL STATS #
Overall 10 of 16
Sector (Life Science) 9 of 15
Type (Divestiture) 2 of 2
State (North Carolina) 1 of 2
Country (United States) 9 of 14
Year (2020) 1 of 4
Size (of disclosed) 10 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-23 Ab Initio Biotherapeutics

San Francisco, California, United States

Ab Initio Biotherapeutics, Inc. is an antigen-discovery company. Antigen design and preparation are the first steps necessary for the discovery of therapeutic antibodies. Ab Initio Biotherapeutics, Inc. was founded in 2015 and is based in San Francisco, California.

Buy $12M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-10 Pfenex

San Diego, California, United States

Pfenex, Inc. is a development and licensing biotechnology company with commercial products focused on leveraging its proprietary protein production platform, Pfenex Expression Technology®, to develop next-generation and novel protein therapeutics to meaningfully improve existing therapies and create novel therapies for biological targets linked to critical, unmet diseases. Pfenex is based in San Diego, California.

Buy $438M

Seller(S) 1

SELLER

Icagen

Durham, North Carolina, United States
Category Company
Founded 1992
Sector Life Science
Employees38
DESCRIPTION

Icagen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-27 Sanofi s Oro Valley

Oro Valley, Arizona, United States

Sanofi's Oro Valley is an opeator of ultra high-throughput biology, screening and chemistry capabilities and research facility in Oro Valley, Arizona.

Buy -
Mergr

Product

Company

Legal